Shopping Cart 0
Cart Subtotal
USD 0

scPharmaceuticals Inc (SCPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

ScPharmaceuticals Inc (scPharmaceuticals) is a clinical-stage pharmaceutical company. The company's pipeline products include subcutaneous formulations of furosemide, ceftriaxone and carbapenem. Its furosemide formulation is a loop diuretic widely used in prescription pharmaceuticals for the management of edema in patients with decompensated heart failure due to the highly variable and overall reduction in the bioavailability of oral formulations. scPharmaceuticals' Ceftriaxone is an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. The company's carbapenems are antibotics used intravenously for the treatment of infections caused by gram-negative organisms. It also provides clinical trial services. scPharmaceuticals is headquartered in Burlington, Massachusetts, the US.

scPharmaceuticals Inc (SCPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

scPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

scPharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

scPharma Raises USD45.6 Million in Series B Financing 11

scPharma Raises USD4 Million in Venture Financing 13

scPharma Raises USD8.18 Million in Venture Financing 14

scPharma Raises USD3.6 Million in Venture Financing 15

scPharma Raises USD3.6 Million in Venture Financing 16

scPharma Raises USD 16 Million In Series A Financing 17

scPharma Raises USD9 Million in Venture Financing 18

Partnerships 19

Sensile Medical Enters Into Co-Development With scPharma 19

scPharma Enters Into Co-Development Agreement With Sensile Medical For Novel Heart Failure Treatment 20

Licensing Agreements 21

scPharmaceuticals Enters into License Agreement with Sensile Medical 21

Equity Offering 22

scPharma Raises USD102 Million in IPO 22

Acquisition 24

Sun Pharma Acquires 14.58% Stake in scPharma for USD13 Million 24

scPharmaceuticals Inc-Key Competitors 25

scPharmaceuticals Inc-Key Employees 26

scPharmaceuticals Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

Aug 14, 2018: scPharmaceuticals announces second quarter 2018 financial results 28

May 07, 2018: scPharmaceuticals Announces First Quarter 2018 Financial Results 29

Mar 20, 2018: scPharmaceuticals Inc. Reports Fourth Quarter 2017 Financial Results 31

Corporate Communications 32

Jun 28, 2018: scPharmaceuticals Names Frederick Hudson As Board Director 32

Apr 26, 2017: John Tucker Appointed as Chief Executive Officer of scPharmaceuticals 33

Product Approvals 34

Nov 06, 2017: First US FDA Submission of Wearable Drug-Device Combination Product Based on Sensile Medicals SensePatch Drug Delivery Technology 34

Nov 02, 2017: scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide) 35

Clinical Trials 36

Jan 24, 2017: scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

scPharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

scPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

scPharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

scPharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

scPharma Raises USD45.6 Million in Series B Financing 11

scPharma Raises USD4 Million in Venture Financing 13

scPharma Raises USD8.18 Million in Venture Financing 14

scPharma Raises USD3.6 Million in Venture Financing 15

scPharma Raises USD3.6 Million in Venture Financing 16

scPharma Raises USD 16 Million In Series A Financing 17

scPharma Raises USD9 Million in Venture Financing 18

Sensile Medical Enters Into Co-Development With scPharma 19

scPharma Enters Into Co-Development Agreement With Sensile Medical For Novel Heart Failure Treatment 20

scPharmaceuticals Enters into License Agreement with Sensile Medical 21

scPharma Raises USD102 Million in IPO 22

Sun Pharma Acquires 14.58% Stake in scPharma for USD13 Million 24

scPharmaceuticals Inc, Key Competitors 25

scPharmaceuticals Inc, Key Employees 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

scPharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ScPharmaceuticals Inc (scPharmaceuticals) is a clinical-stage pharmaceutical company. The company's pipeline products include subcutaneous formulations of furosemide, ceftriaxone and carbapenem. Its furosemide formulation is a loop diuretic widely used in prescription pharmaceuticals for the management of edema in patients with decompensated heart failure due to the highly variable and overall reduction in the bioavailability of oral formulations. scPharmaceuticals' Ceftriaxone is an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. The company's carbapenems are antibotics used intravenously for the treatment of infections caused by gram-negative organisms. It also provides clinical trial services. scPharmaceuticals is headquartered in Burlington, Massachusetts, the US.

scPharmaceuticals Inc (SCPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

scPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

scPharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

scPharma Raises USD45.6 Million in Series B Financing 11

scPharma Raises USD4 Million in Venture Financing 13

scPharma Raises USD8.18 Million in Venture Financing 14

scPharma Raises USD3.6 Million in Venture Financing 15

scPharma Raises USD3.6 Million in Venture Financing 16

scPharma Raises USD 16 Million In Series A Financing 17

scPharma Raises USD9 Million in Venture Financing 18

Partnerships 19

Sensile Medical Enters Into Co-Development With scPharma 19

scPharma Enters Into Co-Development Agreement With Sensile Medical For Novel Heart Failure Treatment 20

Licensing Agreements 21

scPharmaceuticals Enters into License Agreement with Sensile Medical 21

Equity Offering 22

scPharma Raises USD102 Million in IPO 22

Acquisition 24

Sun Pharma Acquires 14.58% Stake in scPharma for USD13 Million 24

scPharmaceuticals Inc-Key Competitors 25

scPharmaceuticals Inc-Key Employees 26

scPharmaceuticals Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

Aug 14, 2018: scPharmaceuticals announces second quarter 2018 financial results 28

May 07, 2018: scPharmaceuticals Announces First Quarter 2018 Financial Results 29

Mar 20, 2018: scPharmaceuticals Inc. Reports Fourth Quarter 2017 Financial Results 31

Corporate Communications 32

Jun 28, 2018: scPharmaceuticals Names Frederick Hudson As Board Director 32

Apr 26, 2017: John Tucker Appointed as Chief Executive Officer of scPharmaceuticals 33

Product Approvals 34

Nov 06, 2017: First US FDA Submission of Wearable Drug-Device Combination Product Based on Sensile Medicals SensePatch Drug Delivery Technology 34

Nov 02, 2017: scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide) 35

Clinical Trials 36

Jan 24, 2017: scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

scPharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

scPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

scPharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

scPharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

scPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

scPharma Raises USD45.6 Million in Series B Financing 11

scPharma Raises USD4 Million in Venture Financing 13

scPharma Raises USD8.18 Million in Venture Financing 14

scPharma Raises USD3.6 Million in Venture Financing 15

scPharma Raises USD3.6 Million in Venture Financing 16

scPharma Raises USD 16 Million In Series A Financing 17

scPharma Raises USD9 Million in Venture Financing 18

Sensile Medical Enters Into Co-Development With scPharma 19

scPharma Enters Into Co-Development Agreement With Sensile Medical For Novel Heart Failure Treatment 20

scPharmaceuticals Enters into License Agreement with Sensile Medical 21

scPharma Raises USD102 Million in IPO 22

Sun Pharma Acquires 14.58% Stake in scPharma for USD13 Million 24

scPharmaceuticals Inc, Key Competitors 25

scPharmaceuticals Inc, Key Employees 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

scPharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.